Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8807275 | Current Research in Translational Medicine | 2017 | 6 Pages |
Abstract
John Cunningham virus (JCV) reactivation, occurring mainly in immunocompromised patients, leads to progressive multifocal leukoencephalopathy, an uncommon but lethal disease. JCV reactivation after T-cell replete haploidentical stem cell transplantation, in the pre-cyclophosphamide era, is poorly represented in the literature. We therefore describe two cases of acute myeloid leukemia who developed JCV reactivation after receiving cyclophosphamide and rituximab post haploidentical stem cell transplantation, and review the literature, aiming to a better understanding of the disease course and its risk factors.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Pathology and Medical Technology
Authors
R. Salem, R. Massoud, S.S. Kanj, M. Hamdan, R. Salman, A. Bazarbachi, J. El-Cheikh,